麻豆国产精品一二三在线观-麻豆国产精品一二三在线观看-麻豆国产精品一区二区-麻豆国产精品永久免费视频-麻豆国产巨作av剧情-麻豆国产蜜桃臀视频在线观看

海普瑞藥業(yè) Hepalink Pharmaceutical   
深圳市海普瑞藥業(yè)股份有限公司是全球最大的肝素鈉原料藥供應(yīng)商，公司產(chǎn)品出口全球，客戶(hù)包括世界知名的跨國(guó)醫(yī)藥企業(yè)，如Sanofi-Aventis，F(xiàn)resenius Kabi，Novartis等。

海普瑞于1998年成立，2007年改制為股份有限公司，2010年5月6日在深交所掛牌上市，證券簡(jiǎn)稱(chēng)“海普瑞”，證券代碼為“002399”。公司注冊(cè)資本80,020萬(wàn)元，總部位于環(huán)境優(yōu)美的深圳市高新技術(shù)園，擁有八家子公司。

多年來(lái)，海普瑞在肝素納產(chǎn)品研發(fā)生產(chǎn)的專(zhuān)業(yè)領(lǐng)域精耕細(xì)作，獨(dú)創(chuàng)了世界領(lǐng)先的肝素鈉“雜質(zhì)與組合分離技術(shù)”、“基團(tuán)完整性保護(hù)和活性釋放技術(shù)”等核心工藝技術(shù)體系， 建立了符合我國(guó)藥品GMP規(guī)范以及美國(guó)和歐盟cGMP藥品規(guī)范和理念的全面質(zhì)量管理體系，公司不僅順利通過(guò)了美國(guó)FDA及歐盟CEP的藥政批準(zhǔn)，還是美國(guó)藥典標(biāo)準(zhǔn)修訂的主要參與者和標(biāo)準(zhǔn)提供者。

海普瑞還先后承擔(dān)了國(guó)家生物高技術(shù)產(chǎn)業(yè)化示范工程項(xiàng)目、國(guó)家火炬計(jì)劃項(xiàng)目、國(guó)家重點(diǎn)技術(shù)創(chuàng)新項(xiàng)目等國(guó)家級(jí)科技項(xiàng)目，為我國(guó)肝素產(chǎn)業(yè)的技術(shù)進(jìn)步、產(chǎn)業(yè)升級(jí)、出口創(chuàng)匯能力的提高做出了重要貢獻(xiàn)， 公司先后取得“國(guó)家技術(shù)創(chuàng)新優(yōu)秀新產(chǎn)品獎(jiǎng) ”、“深圳經(jīng)濟(jì)特區(qū)30年杰出貢獻(xiàn)企業(yè)”、“深圳市優(yōu)秀民營(yíng)企業(yè)”、“深圳市優(yōu)強(qiáng)中小企業(yè)”、“深圳市民營(yíng)領(lǐng)軍骨干企業(yè)”等榮譽(yù)，成為國(guó)家和深圳市的重點(diǎn)高新技術(shù)企業(yè)。

 Shenzhen Hepalink Pharmaceutical Co., Ltd (Hepalink) is the largest supplier of Heparin Sodium API in the world, distributing its products in the global markets and internationally renowned pharmaceutical companies, e.g. Sanofi-Aventis, Fresenius Kabi, and Novartis.

Hepalink was established in 1998 and restructured in 2007 to be a limited liability company. Hepalink went public and was listed on the Shenzhen Stock Exchange on May 6, 2010 (stock code "002399"). Hepalink headquarters are located in the Shenzhen High-Tech Park.

Hepalink has created a proprietary process for dealing with impurities and composition separation and activity release technologies. Hepalink has established a comprehensive quality management system in line with China GMP standards and the US and European cGMP standards and regulations. Hepalink is approved by the U.S. FDA and EU regulatory authorities, and it is also one of the primary participants in the revision of the USP pharmacopeia standards.

Hepalink also has successfully undertaken National Science and Technology Projects, such as National Bio-tech Industrialization Demonstration Project, National Torch Project, and National Key Technology Innovation Project. Through these projects, Hepalink has made a significant contribution to the technological progress of China's Heparin industry, and export capabilities.

Hepalink, as a leading high-tech enterprise has received numerous awards, including the National Award for Technology Innovation and Outstanding New Products, Enterprise with Outstanding Contribution for the Past 30 Years in the Shenzhen Special Economic Zone, Shenzhen Excellent Private Enterprise, Shenzhen Excellent and Strong SME, and Shenzhen Leading Private Enterprise.